Diaverum’s study reveals factors associated with incidence and severity of COVID-19 in CKD patients
Diaverum, a leading global renal care service provider headquartered in Sweden, has conducted a large multi-national study that determines factors affecting incidence and outcome of COVID-19 in patients with chronic kidney disease (CKD) receiving hemodialysis treatment.The COVID-19 pandemic has had a particularly hard impact on patients with chronic diseases. Worldwide, almost 3 million people receive regular dialysis treatment, with preliminary reports indicating that mortality from COVID-19 is especially high among these patients.
Dr Fernando Macário, Diaverum’s chief medical officer,